Boehringer Ingelheim licenses ProBioGen's novel GlymaxX® technology
Ingelheim and Berlin, Germany, 10 August 2011 – Boehringer Ingelheim and ProBioGen AG announced today that they have signed a non-exclusive Licensing Agreement regarding ProBioGen’s GlymaxX® technology. Boehringer Ingelheim’s Contract Manufacturing Business will apply the technology to enhance ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) activity of antibodies.
The GlymaxX® technology for production of
afucosylated proteins is universally applicable, simple and potent.
As a unique feature, differentiating it from other approaches, the
GlymaxX® technology can also be applied to already existing
antibody producer cell lines without altering their productivity.
The technology can easily be integrated into Boehringer
Ingelheim’s high expression CHO-based BI-HEX®
Both parties agreed to jointly market the technology and to offer it to customers royalty free.